{"id":"https://openalex.org/W2366717010","doi":null,"title":"Clinical efficacy and safety of bevacizumab in combination with chemotherapy in the treatment of recurrent ovarian cancer by retrospective analysis","display_name":"Clinical efficacy and safety of bevacizumab in combination with chemotherapy in the treatment of recurrent ovarian cancer by retrospective analysis","alternate_titles":[],"publication_year":2015,"publication_date":"2015-01-01","ids":{"openalex":"https://openalex.org/W2366717010","mag":"2366717010"},"language":"en","primary_location":{"id":"mag:2366717010","doi":null,"is_oa":false,"landing_page_url":"https://oversea.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&filename=GLYZ201515010","pdf_url":null,"source":{"id":"https://openalex.org/S2764396500","display_name":"The Chinese Journal of Clinical Pharmacology","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/P4320800687","host_organization_name":"Chinese Pharmaceutical Association","host_organization_lineage":["https://openalex.org/P4320800687"],"host_organization_lineage_names":["Chinese Pharmaceutical Association"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"The Chinese Journal of Clinical Pharmacology","raw_type":null},"parent_works":[],"lineage":["https://openalex.org/W2366717010"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5100380251","display_name":"Yan Li","orcid":"https://orcid.org/0000-0001-6018-6538","observed_orcids":["https://orcid.org/0000-0001-6018-6538"]},"institutions":[{"id":"https://openalex.org/I4210093964","display_name":"Peking University Cancer Hospital","ror":"https://ror.org/00nyxxr91","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210093964"]}],"countries":["CN"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Yan Li","raw_affiliation_strings":["Department of Gynecological Oncology,Beijing Cancer Hospital"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Gynecological Oncology,Beijing Cancer Hospital","institution_ids":["https://openalex.org/I4210093964"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5100380251"],"corresponding_institution_ids":["https://openalex.org/I4210093964"],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":1,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":86,"max":92},"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10550","display_name":"Ovarian cancer diagnosis and treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10550","display_name":"Ovarian cancer diagnosis and treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10668","display_name":"Endometrial and Cervical Cancer Treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2729","display_name":"Obstetrics and Gynecology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":1.0},{"id":"https://openalex.org/keywords/recurrent-ovarian-cancer","display_name":"recurrent ovarian cancer","score":0.9990000128746033},{"id":"https://openalex.org/keywords/platinum-refractory-ovarian-cancer","display_name":"platinum-refractory ovarian cancer","score":0.9409999847412109},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.8569999933242798},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.7829999923706055},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.984000027179718},{"id":"https://openalex.org/keywords/ca125","display_name":"CA125","score":0.8429999947547913},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.7009999752044678},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.9660000205039978},{"id":"https://openalex.org/keywords/thrombocytopenia","display_name":"thrombocytopenia","score":0.9879999756813049}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8742104768753052},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.8562227487564087},{"id":"https://openalex.org/C2780427987","wikidata":"https://www.wikidata.org/wiki/Q172341","display_name":"Ovarian cancer","level":3,"score":0.6734890937805176},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.6329792141914368},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6096991300582886},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.595617949962616},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.5791289210319519},{"id":"https://openalex.org/C2780580376","wikidata":"https://www.wikidata.org/wiki/Q186889","display_name":"Nausea","level":2,"score":0.5598731637001038},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5329820513725281},{"id":"https://openalex.org/C2780852908","wikidata":"https://www.wikidata.org/wiki/Q127076","display_name":"Vomiting","level":2,"score":0.48091575503349304},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.47486138343811035},{"id":"https://openalex.org/C2779984678","wikidata":"https://www.wikidata.org/wiki/Q2145898","display_name":"Response Evaluation Criteria in Solid Tumors","level":4,"score":0.46383389830589294},{"id":"https://openalex.org/C167135981","wikidata":"https://www.wikidata.org/wiki/Q2146302","display_name":"Retrospective cohort study","level":2,"score":0.4277956485748291},{"id":"https://openalex.org/C3019864225","wikidata":"https://www.wikidata.org/wiki/Q5867482","display_name":"Combination chemotherapy","level":3,"score":0.4253776967525482},{"id":"https://openalex.org/C2777793932","wikidata":"https://www.wikidata.org/wiki/Q1116229","display_name":"Common Terminology Criteria for Adverse Events","level":3,"score":0.42024779319763184},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.40231576561927795},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.36224624514579773},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.21977335214614868}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2366717010","doi":null,"is_oa":false,"landing_page_url":"https://oversea.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&filename=GLYZ201515010","pdf_url":null,"source":{"id":"https://openalex.org/S2764396500","display_name":"The Chinese Journal of Clinical Pharmacology","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/P4320800687","host_organization_name":"Chinese Pharmaceutical Association","host_organization_lineage":["https://openalex.org/P4320800687"],"host_organization_lineage_names":["Chinese Pharmaceutical Association"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"The Chinese Journal of Clinical Pharmacology","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1964435145","https://openalex.org/W3031655345","https://openalex.org/W164100026","https://openalex.org/W2231393048","https://openalex.org/W1987310294","https://openalex.org/W2069342331","https://openalex.org/W2518280339","https://openalex.org/W2990048933","https://openalex.org/W788841912","https://openalex.org/W2171762826"],"abstract_inverted_index":{"Objective":[0],"To":[1],"evaluate":[2],"the":[3,14,39,67,82,121,133,196],"clinical":[4,184],"efficacy":[5,68],"and":[6,45,69,78,90,101,116,124,155,164,173,181],"safety":[7],"of":[8,16,42,59,98],"bevacizumab":[9,32,60,186],"combined":[10,33,187],"with":[11,26,31,34,64,149],"chemotherapy":[12,35,188],"in":[13,47,86],"treatment":[15,193],"recurrence":[17],"ovarian":[18,23,201],"cancer.":[19,202],"Methods":[20],"Thirty":[21],"seven":[22],"cancer":[24,91],"patients":[25,53,144],"complete":[27,142],"data":[28,40,97],"who":[29],"treated":[30],"were":[36,105,113,168],"reviewed":[37],"from":[38],"bases":[41],"our":[43],"hospital":[44],"included":[46,52],"this":[48],"retrospective":[49],"study.":[50],"All":[51],"received":[54],"more":[55],"than":[56],"2":[57,158],"cycles":[58],"based":[61],"combination":[62],"therapy":[63],"eligible":[65],"for":[66,132,151,195],"toxicity":[70,163,167,180],"assessments.":[71],"The":[72,96,127,140,160],"objective":[73,110],"response":[74,83,111,143],"rate":[75,112],"was":[76,136],"recorded":[77],"evaluated":[79],"according":[80],"to":[81],"evaluation":[84],"criteria":[85,123],"solid":[87],"tumors(":[88],"RECIST)":[89],"antigen":[92],"125(":[93],"CA125)":[94],"criteria.":[95,126],"survival":[99,131],"time":[100],"adverse":[102],"drug":[103],"reactions":[104],"analysised.":[106],"Results":[107],"After":[108],"treatment,the":[109],"32.":[114],"4%":[115],"43.":[117],"2%":[118],"respectively":[119],"by":[120],"RECIST":[122],"CA125":[125],"median":[128],"progression":[129],"free":[130],"37":[134],"cases":[135],"5.":[137],"4":[138],"months.":[139,159],"two":[141],"had":[145],"longest":[146],"DFS":[147],"interval":[148],"one":[150],"10.":[152],"0":[153],"months":[154],"another":[156],"for11.":[157],"main":[161],"hematologic":[162,166],"non-":[165],"grade":[169],"\u2160-":[170],"\u2161":[171],"neutropenia,thrombocytopenia,nausea":[172],"vomiting":[174],"et":[175],"al.":[176],"Conclusion":[177],"With":[178],"acceptable":[179],"relative":[182],"well":[183],"activity,the":[185],"can":[189],"be":[190],"a":[191],"potential":[192],"modality":[194],"recurrent":[197],"or":[198],"platinum-":[199],"refractory":[200]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2366717010","counts_by_year":[{"year":2021,"cited_by_count":1}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2016-06-24T00:00:00"}
